cvs health glp-1 receptor agonist weight management diabetes treatments A customizable approach to cost for GLP-1s GLP-1 Medications for Weight Loss
Description
Challenges: A major challenge for Eli Lilly will be to effectively differentiate Mounjaro from semaglutide
References: Drucker, D
A few months later the drug gained authorisation in Canada, the European Union, Japan and then Australia in 2019
Preliminary safety analyses indicate that tirzepatide does not cause severe hypoglycemia and shows no adverse effects on central respiratory control (59)
,aspect=ignore)
If after a month someone isnt having significant side effects and isnt losing weight too quickly, then Ill increase the dose. Both medications are given as once-weekly injections using prefilled pens
